EC
OVID icon

EcoR1 Capital’s Ovid Therapeutics OVID Stock Holding History

EcoR1 Capital’s Portfolio OVID Stock Details OVID Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-6,117,400
Closed -$18.7M – 63
2024
Q1 		$18.7M Hold
6,117,400
– – 0.47% 38
2023
Q4 		$19.7M Hold
6,117,400
– – 0.51% 31
2023
Q3 		$23.5M Hold
6,117,400
– – 0.79% 25
2023
Q2 		$20.1M Hold
6,117,400
– – 0.49% 28
2023
Q1 		$15.8M Hold
6,117,400
– – 0.51% 31
2022
Q4 		$11.4M Hold
6,117,400
– – 0.35% 35
2022
Q3 		$11.3M Hold
6,117,400
– – 0.33% 36
2022
Q2 		$13.2M Hold
6,117,400
– – 0.45% 36
2022
Q1 		$19.2M Buy
6,117,400
+35,200
+0.6% +$111K 0.6% 32
2021
Q4 		$19.5M Hold
6,082,200
– – 0.62% 27
2021
Q3 		$20.4M Hold
6,082,200
– – 0.71% 26
2021
Q2 		$23.8M Hold
6,082,200
– – 0.89% 26
2021
Q1 		$24.4M Buy
+6,082,200
New +$20.2M 1.08% 23

Other funds holding OVID

TPC
Takeda Pharmaceutical Company Tokyo, Japan $16.4M AUM 195.92% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
KCM
Kennedy Capital Management St Louis, Missouri $5.65B AUM 61.31% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

EcoR1 Capital's OVID Position: Q2 2024 in Review

EcoR1 Capital sold out of Ovid Therapeutics (OVID) in Q2 2024, closing a stake of 6,117,400 shares — an estimated $18.7M sold.

EcoR1 Capital first reported a position in OVID in Q1 2021 and held it in 13 quarters. The position peaked at $24.4M in Q1 2021. 74 funds tracked by Wall St. Rank hold OVID as of Q2 2024.

  • EcoR1 Capital reported no remaining Ovid Therapeutics position as of Q2 2024 after selling out during the quarter.
  • EcoR1 Capital sold 6,117,400 Ovid Therapeutics shares in Q2 2024, an estimated $18.7M.
  • EcoR1 Capital first reported a position in Ovid Therapeutics in Q1 2021 and held it in 13 quarters.
  • EcoR1 Capital's Ovid Therapeutics position peaked at $24.4M in Q1 2021.
  • 74 funds tracked by Wall St. Rank held Ovid Therapeutics as of Q2 2024.

Based on EcoR1 Capital's 13F filing for Q2 2024, filed 14 Aug 2024.